Incyte
Incyte Corporation, a leading biopharmaceutical company headquartered in the United States, has been at the forefront of innovative cancer therapies since its founding in 1991. With a strong focus on oncology, Incyte develops and commercialises novel treatments that address unmet medical needs, particularly in the fields of haematology and solid tumours. The company is renowned for its flagship product, Jakafi (ruxolitinib), which was the first FDA-approved JAK1/JAK2 inhibitor, offering unique therapeutic options for patients with myelofibrosis and polycythaemia vera. Incyte's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, with a robust pipeline of investigational therapies aimed at improving patient outcomes. With a global presence, Incyte continues to make significant strides in advancing cancer care and enhancing the quality of life for patients worldwide.
DitchCarbon Score
How does Incyte's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Incyte's score of 33 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Incyte's reported carbon emissions
Incyte, headquartered in the US, reported its carbon emissions for 2023, totalling approximately 9,351,000 kg CO2e for Scope 1 emissions, 6,079,000 kg CO2e for Scope 2 emissions (location-based), and 12,924,000 kg CO2e for Scope 3 emissions. This reflects a significant commitment to transparency in its environmental impact. In 2022, Incyte's emissions were approximately 8,062,000 kg CO2e for Scope 1, 6,375,000 kg CO2e for Scope 2, and 10,917,000 kg CO2e for Scope 3. The company has shown a trend of increasing emissions over the years, with 2021 figures at 6,371,000 kg CO2e (Scope 1), 5,607,000 kg CO2e (Scope 2), and 4,224,000 kg CO2e (Scope 3). Despite the lack of specific reduction targets or initiatives disclosed, Incyte's emissions data indicates a focus on understanding and managing its carbon footprint across all three scopes. The company has not set formal reduction targets under the Science Based Targets initiative (SBTi) or other climate pledges, which may suggest an area for future commitment. Overall, Incyte's emissions data highlights the importance of ongoing monitoring and potential for future climate action as part of its corporate responsibility strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 4,775,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 7,451,000 | 0,000,000 | 000,000 | 0,000,000 | 000,000 |
| Scope 3 | 7,165,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Incyte is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
